STOCK TITAN
  1. Home
  2. News
  3. AMYT
  4. Director/PDMR Shareholding

Director/PDMR Shareholding

Amryt (Nasdaq: AMYT, AIM: AMYT) announced the grant of 3,431,350 share options to CEO Joe Wiley and CFO Rory Nealon, approved by the Remuneration Committee.

Rhea-AI Impact
(Low)
Rhea-AI Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Tags

Rhea-AI Summary

Amryt (Nasdaq: AMYT, AIM: AMYT) announced the grant of 3,431,350 share options to CEO Joe Wiley and CFO Rory Nealon, approved by the Remuneration Committee. The exercise price is set at US$2.804 per Share. Options can be exercised in increments over three years, with 25% available after 12 months. All options are subject to change of control provisions and expire seven years post-grant. Following this grant, Wiley holds 8,468,810 options and Nealon holds 6,226,823 options, reflecting their commitment to the company's growth.

Loading translation...

Positive

  • Grant of 3,431,350 share options to key executives, indicating management confidence and alignment with shareholder interests.
  • Options are structured to incentivize long-term performance with a vesting schedule.

Negative

  • None.
Argus Session date unavailable
-0.93% session move Open Argus
Details

News Market Reaction – AMYT

The recorded move for AMYT in the trading session of this news was -0.93%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities

DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options ("Options") to subscribe for ordinary shares in the Company ("Shares") under the Employee Share Option Plan 2019 (the "Plan") to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.

The Options have an exercise price of US$2.804 per Share ($14.02 per ADS equivalent) ("Exercise Price"). These options may be exercised as follows:

●25% of the total Options granted may be exercised 12 months after the date of grant;
●a further 25% of the total Options granted may be exercised 24 months after the date of grant; and
●the balance of the Options may be exercised 36 months after the date of grant.

All Options are subject to change of control provisions and expire on the seventh anniversary of their grant.

Following the grants of these options, the following Director and Company Secretary have the following options:

Director / Company SecretaryOptions grantedTotal Options now held
Joe Wiley2,031,3508,468,810
Rory Nealon1,400,0006,226,823

PDMR Dealings

The notification of dealing forms for each Director/Company Secretary can be found below.  This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

1.           Details of the person discharging managerial responsibilities / person closely associated
a)NameJoe Wiley
2.Reason for the notification
a)Position / status